Annual report pursuant to Section 13 and 15(d)

Earnings (Loss) Per Common Share (Tables)

v3.22.2.2
Earnings (Loss) Per Common Share (Tables)
12 Months Ended
Jun. 30, 2022
Earnings (Loss) Per Common Share [Abstract]  
Schedule of Earnings (loss) Per Share, Basic and Diluted

Year Ended

June 30, 

2022

    

2021

Basic and diluted numerator:

Net loss attributable to iBio, Inc.

$

(50,303)

    

$

(23,207)

Preferred stock dividends – iBio CMO Preferred Tracking Stock

 

(88)

 

(260)

Net loss available to iBio, Inc. stockholders

$

(50,391)

$

(23,467)

 

 

Basic and diluted denominator:

 

 

 

 

Weighted-average common shares outstanding

 

8,721

 

7,825

 

 

Per share amount

$

(5.78)

$

(3.00)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

In Fiscal Years 2022 and 2021, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of June 30, 2022 and 2021, shares issuable which could potentially dilute future earnings included were as follows:

June 30, 

    

2022

    

2021

(in thousands)

Stock options

 

622

 

342

Warrant issued under the Transaction

    

51

    

Restricted stock units

 

21

 

27

Series 2022 Preferred

*

Shares excluded from the calculation of diluted loss per share

 

694

 

369

* Less than 1,000